Pruritis clinical trials

Explore recruiting pruritis clinical trials.

Recruiting pruritis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pruritis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)

Poland, Germany, Spain, Estonia, Hungary, France +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis (ONWARD1)

Bulgaria, Belgium, Portugal, Poland, Czechia, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Botox Treatment for Patients with Hidradenitis Suppurativa: A Within-Person, Randomized, Double-blind, Controlled Study

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects with Primary Biliary Cholangitis

Iceland

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of 3 subcutaneous dose regimens of lunsekimig (SAR443765) in adult participants with moderate to-severe atopic dermatitis

Czechia, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis

Sweden, Germany, Spain, Denmark, Belgium, Hungary +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Pruritis trials by city

Pruritis in Toronto Pruritis in Vancouver Pruritis in Montreal Pruritis in Calgary Pruritis in Edmonton Pruritis in Ottawa Pruritis in Winnipeg Pruritis in Quebec City Pruritis in Hamilton Pruritis in Kitchener Pruritis in London Pruritis in Halifax Pruritis in New York Pruritis in Los Angeles Pruritis in Chicago Pruritis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease